Astra Zeneca D3614C00001 - A Phase III Double-blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First-Line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer
This purpose of this research study is to find out if a new medication called capivasertib given with one of the standards of care paclitaxel will work more effectively than paclitaxel alone as first line treatment of locally advanced (inoperable) or metastatic triple negative breast cancer.
Principal Investigator
William W. MacLaughlin, MD
Contact
Ora Mae Jackson, RN, OCN
757-534-5565
[email protected]
Locations
Peninsula Cancer Institute
12100 Warwick Blvd. Suite 201
Newport News, VA 23601
Cancer Specialists of Tidewater
110-E Wimbledon Square
Chesapeake, VA 23320
Status
Recruiting
Category
Oncology
Study #